|Day Low/High||63.67 / 65.41|
|52 Wk Low/High||52.04 / 77.03|
Now for those of you haven't voted, please go and do so and don't vote this stuff just invest in it!
Things may pick up in the afternoon -- here is how to play it and what sectors to be wary of.
Straying from these names could land you in quicksand as the 4th quarter begins.
This important number can be quite predictive about what's likely to occur with a stock's price.
The key business statistic can be quite predictive about what's likely to occur with a stock's price.
Five Below's earnings and sales growth is impressive, but earnings per share comparison to its direct competitors make it expensive.
We forgot that this nation is a nation based on consumption, not on industry, on sales, not on making things.
Two companies, PepsiCo and Constellation Brands, are disrupting their own businesses and getting no credit whatsoever for doing so.
Family offices, which manage billions of dollars and have much fewer restrictions on how they deploy capital, have been wading into the cannabis space with increasing frequency.
Contrarians who bought several "dead men walking" retailers have pocketed big gains by defying conventional wisdom.
Rite Aid CEO John Standley faces shareholders's scrutiny after the merger flop.
After a failed merger with Albertsons, Rite Aid faces a difficult time on its own in a changing landscape.
A week of bad news for Ride Aid may be good news for its competitors Walgreens and CVS.
The Nasdaq was the lone major index to close the day on a high note.
Sometimes you gotta have faith, but you also have to be a little more skeptical.
The erratic CEO and awful fundamentals make it impossible to value TSLA -- despite attractive technicals.
Prime Day 2018 is expected to generate $3.4 billion in sales, according to Coresight Research.
Here's to FANG for once again exciting and enthralling and defying all of the negatives.
Amazon's acquisition of PillPack is hitting traditional pharmacies.
More bullish signals are visible so let's do a top to bottom review of the charts and indicators.
The drugstore chain's price to fair value has not been this favorable since the Crash of 2008-2009.
Theranos, once a Silicon Valley unicorn promising investors and partners like Walgreens a simple blood-testing solution, is a cautionary tale for biotech investors.
Few companies can match CVS' long-term record and top-quality corporate metrics.
Consistency in discipline will make the difference.
Stock markets ran higher as investors turned towards domestic-focused companies.
Better-than-expected earnings will help soothe market jitters in the second quarter.